BioVie specializes in the development of innovative solutions for the treatment of neurodegenerative and liver diseases.
BioVie has raised $12.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in August 2025.
BioVie's investors include Avenue Capital Group.
BioVie is headquartered in Beverly, United States.
BioVie specializes in the development of innovative solutions for the treatment of neurodegenerative and liver diseases.
BioVie is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BioVie — Funding & Investors." VCBacked, August 7, 2025, https://www.vcbacked.co/company/biovie. Accessed November 13, 2026.
VCBacked. (2025). BioVie — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/biovie
{{cite web |title=BioVie — Funding & Investors |url=https://www.vcbacked.co/company/biovie |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at BioVie? Request a listing update